Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00566553 · ClinicalTrials.gov registry record · NA

The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women

A NA study, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
39
Enrollment target

NCT00566553: Completed NA study, sponsored by Mayo Clinic.

NCT00566553 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00566553, a NA study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
39 participants
Enrollment target

Study Summary

The role of estrogens in the pathogenesis of breast cancer has been well documented. This has led to the development of "Anti-Estrogens" (selective estrogens receptor modulators and Aromatase Inhibitors), used for treatment and prevention of breast cancer. These agents, however, have significant side effects, which are not acceptable to many healthy high-risk women. There is preliminary evidence that grape seed extract acts as "natural" aromatase inhibitor (1). This study has the potential to quantify the effectiveness of a natural substance that mimics the action of pharmaceutical aromatase inhibitors.

Interventions

  • DIETARY_SUPPLEMENT Grape Seed Extract

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2008-02
Est. Completion 2011-09
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT00566553

The ClinicalTrials.gov registry entry for NCT00566553 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Grape Seed Extract is the first listed.

NCT00566553 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00566553 about?

NCT00566553 is a clinical study titled "The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women". The role of estrogens in the pathogenesis of breast cancer has been well documented. This has led to the development of "Anti-Estrogens" (selective estrogens receptor modulators and Aromatase Inhibitors), used for treatment and prevention of breast cancer. These agents, however, have significant sid...

What is the current status of trial NCT00566553?

This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2008-02. Estimated completion is 2011-09.

What interventions are being tested in trial NCT00566553?

The interventions under investigation include: Grape Seed Extract (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00566553?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.